Zhang Quane, Wang Yifan, Shi Wenting, Chen Yue, He Zhengmei, Yu Liang, Wang Chunling
Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huai'an, China.
Sci Rep. 2025 Jan 13;15(1):1819. doi: 10.1038/s41598-024-84343-x.
Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated. In our study, we included 122 newly diagnosed MM patients who were treated with bortezomib-based chemotherapy. These patients were divided into low-PLR and high-PLR groups based on their initial PLR values. We compared the clinical characteristics between the two groups and utilized restricted cubic splines (RCSs) in the regression model to estimate the nonlinear relationship between the initial PLR and overall survival (OS) in MM patients. The results showed that patients in the low-PLR group had significantly worse OS (P = 0.00031) and progression-free survival (PFS) (P < 0.0001) compared to those in the high-PLR group. Furthermore, within the higher-risk MM group, a low PLR was also associated with worse OS (P = 0.0037) and PFS (P = 0.0048). Therefore, a low PLR was identified as an independent predictor of poor OS in MM patients. The RCS curves further confirmed a significant nonlinear relationship between the PLR and OS in patients with MM. The PLR may serve as a significant independent prognostic indicator for MM patients undergoing bortezomib-based chemotherapy, and there exists a crucial nonlinear relationship between the PLR and OS in these patients.
多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤。先前的研究已证实血小板与淋巴细胞比值（PLR）在某些实体瘤患者中的预后意义。然而，PLR与骨髓瘤患者预后之间的关系尚未明确阐明。在我们的研究中，我们纳入了122例接受以硼替佐米为基础的化疗的新诊断MM患者。这些患者根据其初始PLR值分为低PLR组和高PLR组。我们比较了两组之间的临床特征，并在回归模型中使用受限立方样条（RCS）来估计MM患者初始PLR与总生存期（OS）之间的非线性关系。结果显示，与高PLR组患者相比，低PLR组患者的OS（P = 0.00031）和无进展生存期（PFS）（P < 0.0001）明显更差。此外，在高危MM组中，低PLR也与较差的OS（P = 0.0037）和PFS（P = 0.0048）相关。因此，低PLR被确定为MM患者OS不良的独立预测因素。RCS曲线进一步证实了MM患者PLR与OS之间存在显著非线性关系。PLR可能是接受以硼替佐米为基础化疗的MM患者的重要独立预后指标，并且这些患者的PLR与OS之间存在关键的非线性关系。
